Tango Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Tango Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 2.85M shares, a 3376.19% increase year-over-year.
- Tango Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 2.55M shares, a 239556.97% increase year-over-year.
- Tango Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 1.35M shares, a 594.70% increase year-over-year.
- Tango Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 674.38K shares, a 96.44% increase year-over-year.
- Tango Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 2.11M shares, a 101.57% increase from fiscal 2024.
- Tango Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 1.05M shares, a 109.44% increase from fiscal 2023.
- Tango Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 498.97K shares, a 7.28% increase from fiscal 2022.
- Tango Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 465.11K shares, a 27.18% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 2.85M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 7.42M shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 2.55M shares 10-Q · filed 2026-05-13 | 4.65M shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | 1.35M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 2.11M shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 674.38K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 951.71K shares derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | 82.08K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 620.64K shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 1.06K shares 10-Q · filed 2025-05-12 | 712.62K shares derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-12-31 | 194.19K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 1.05M shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 343.31K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 1.10M shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 174.06K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 947.33K shares derived: sum of 4 quarters · filed 2024-08-07 |
| 2024-03-31 | 333.51K shares 10-Q · filed 2024-05-08 | 801.89K shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 252.13K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | 498.97K shares 10-K · filed 2024-03-18 |
| 2023-09-30 | 187.64K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 285.44K shares derived: sum of 4 quarters · filed 2023-11-08 |
| 2023-06-30 | 28.62K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | 167.11K shares derived: sum of 4 quarters · filed 2023-08-07 |
| 2023-03-31 | 30.59K shares 10-Q · filed 2023-05-09 | 384.39K shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 38.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | 465.11K shares 10-K · filed 2023-03-27 |
| 2022-09-30 | 69.31K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 480.71K shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 245.90K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | |
| 2022-03-31 | 111.31K shares 10-Q · filed 2022-05-11 | |
| 2021-12-31 | 54.19K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | 638.75K shares 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |